Special Edition: Spotlight on NSCLCJune 29, 2020 | Oncology Geriatrics Low-Dose Erlotinib an Option for Frail or Elderly Patients w. NSCLC? According to the results of a single-arm, multicenter phase 2 trial in JAMA Oncology, low-dose erlotinib may be a safe and effective option for frail or elderly patients with EGFR mutation-positive NSCLC. Read full article Hematology FoundationOne CDx Approved as Companion Diagnostic for Capmatinib for METex14 NSCLC The approval of capmatinib and its companion diagnostic is the first of its kind for this specific diagnosis, using next-generation sequencing to perform comprehensive genomic profiling of solid tumors. It now has FDA approval for 21 different agents. Read full article Hematology ALK-Rearranged NSCLC Linked to Higher Venous and Arterial Thrombotic Risk The findings, recently published in the Journal of Thoracic Oncology, suggested that patients with ALK rearrangements may benefit from prophylactic anticoagulation, and venous thromboembolism risk prediction scores may improve if ALK rearrangement status is incorporated. Read full article
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS